Literature DB >> 7593809

Genitourinary tumors in men with the Muir-Torre syndrome.

D A Davis1, P R Cohen.   

Abstract

The Muir-Torre syndrome is an autosomal dominant genodermatosis characterized by the occurrence of one or more sebaceous gland tumors (either adenoma, epithelioma, or carcinoma) and a single malignant internal neoplasm. To date, 133 cases of Muir-Torre syndrome have been described. Colorectal (49%) and genitourinary (21%) carcinomas are the most common initial neoplasms. The case of a man with a history of recurrent ocular sebaceous carcinoma who subsequently had seminoma is described, and previously published reports of men with Muir-Torre syndrome and genitourinary tumors are discussed. Including this report, an associated genitourinary tumor was the initial malignant internal neoplasm in 11 men with Muir-Torre syndrome. The detection of a genitourinary neoplasm preceded diagnosis of the patient's Muir-Torre syndrome-associated sebaceous gland tumor in five patients (45%). All patients with sebaceous gland tumors of the type associated with Muir-Torre syndrome warrant consideration of Muir-Torre syndrome and appropriate workup to detect asymptomatic malignant visceral neoplasms.

Entities:  

Mesh:

Year:  1995        PMID: 7593809     DOI: 10.1016/0190-9622(95)90435-2

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

Review 1.  Lower gastrointestinal tract cancer predisposition syndromes.

Authors:  Neel B Shah; Noralane M Lindor
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

Review 2.  Familial and genetic risk of transitional cell carcinoma of the urinary tract.

Authors:  Christine M Mueller; Neil Caporaso; Mark H Greene
Journal:  Urol Oncol       Date:  2008-06-18       Impact factor: 3.498

3.  Clinical Features and Prognosis of Young and Middle-Aged Adults With Skin Sebaceous Adenocarcinoma.

Authors:  Fan Wang; Xiu-Yun Wang; Xian Jiang
Journal:  Dermatol Surg       Date:  2022-06-21       Impact factor: 2.914

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.